BioSpace News Archive

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its third quarter 2022 financial results on Monday, November 7, 2022, at 8:30 AM Eastern time.

Monte Rosa Therapeutics, Inc., a biotechnology company developing novel molecular glue degrader-based medicines, announced the company will participate in the following upcoming investor conferences.

Cytek Biosciences, Inc. announced that Chris Williams has been appointed chief operating officer for the company.

United Therapeutics Corporation announced that a preliminary analysis of the EXPEDITE study in patients suffering from World Health Organization Group 1 pulmonary arterial hypertension demonstrated that 79% of patients in the study achieved an Orenitram extended-release tablet dose of at least 4 mg three times daily, for a 12 mg total daily dose at 16 weeks, after an up to eight week induction treatment period with Remodulin injection.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating certain inflammatory and oncological conditions, today announced it has engaged SC&H Capital, an affiliate of SC&H Group

The International Photodynamic Association (IPA) is pleased to announce that Professor Xiuli Wang, Shanghai Skin Disease Hospital, Tongji University School of Medicine (China), is the recipient of the 2022 Clinical PDT Research Excellence Award.

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its seventh ADMA BioCenters plasma collection facility located in Greensboro, North Carolina.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced that it will provide business updates and report financial results for the third quarter ended September 30, 2022 on Monday, November 7, 2022 and will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Centessa Pharmaceuticals plc announced that members of its management team will participate in the following investor conferences:

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”) today announces that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the “MHRA”) and the Research Ethics Committee to initiate a Phase I study of SPL028, its proprietary deuterated N, N-dimethyltryptamine (“DMT”) candidate, with supportive therapy in healthy volunteers.